• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of International Medical Research >Cardiotoxicity of trastuzumab emtansine (T-DM1): a single-center experience
【24h】

Cardiotoxicity of trastuzumab emtansine (T-DM1): a single-center experience

机译：Trastuzumab Omtansine（T-DM1）的心脏毒性：单中心经验

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective New anti-cancer drugs promise to increased survival benefits and reduce adverse events. Trastuzumab emtansine (T-DM1) is a novel anti-human epidermal growth factor receptor 2 agent that has shown minimal cardiotoxicity in clinical trials. However, data on real-life outcomes are required. Methods A retrospective review of our center’s medical records was performed, including female patients aged ≥18 years with a diagnosis of metastatic breast cancer who were treated with T-DM1. Descriptive statistics were used to investigate clinical features that could increase the risk of cardiotoxicity. Cardiotoxicity was determined by comparing pre and post-T-DM1 echocardiogram results and was defined as a decrease in the left ventricular ejection fraction (LVEF) &10% to below 55%. Results Data from 41 female patients with a mean age of 52?±?11.5 years were evaluated. A significant LVEF decrease (from 59% to 33%) was observed in one patient during T-DM1 treatment. Further investigation showed that this decrease was due to underlying coronary artery disease, and LVEF recovered to the baseline value after coronary revascularization. Conclusion T-DM1 seems to be safe in terms of cardiotoxicity. Real-life data with a larger sample size are still needed to confirm the cardiac safety of T-DM1.
机译：目标新的抗癌药物承诺增加生存效益，减少不良事件。 Trastuzumab Emtansine（T-DM1）是一种新型的抗人表皮生长因子受体2剂，其在临床试验中显示出最小的心脏毒性。但是，需要关于现实生活结果的数据。方法对我们中心的病历进行回顾性审查，包括≥18岁的女性患者，诊断用T-DM1治疗转移性乳腺癌。描述性统计用于调查可能增加心脏毒性风险的临床特征。通过比较预和T-DM1超声心动图结果来确定心脏毒性，并且被定义为左心室喷射分数（LVEF）＆amp的降低; 10％至低于55％。结果来自41名雌性患者的患者，平均年龄为52岁？±11.5岁。在T-DM1处理期间，在一名患者中观察到显着的LVEF减少（从59％到33％）。进一步的研究表明，这种减少是由于冠状动脉疾病的潜在冠状动脉疾病，并且在冠状动脉血运重建后恢复到基线值的LVEF。结论T-DM1似乎在心脏毒性方面是安全的。仍然需要具有较大样本大小的现实生活数据来确认T-DM1的心脏安全性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号